Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1658824 | 0.83 | BAZ2B (0.43) | BAZ2BRXFP1NPC1RAB9AALDH1A1 | |
| SCHEMBL30957414 | 0.81 | BAZ2B (0.42) | BAZ2BRXFP1NPC1RAB9AALDH1A1 | |
| SCHEMBL15300166 | 0.81 | BAZ2B (0.42) | BAZ2BRXFP1NPC1RAB9AALDH1A1 | |
| SCHEMBL4814588 | 0.78 | NPC1 (0.56) | NPC1RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL5341323 | 0.75 | RXFP1 (0.35) | BAZ2BRXFP1NPC1RAB9AALDH1A1 | |
| SCHEMBL25082660 | 0.74 | ALDH1A1 (0.43) | BAZ2BRXFP1NPC1RAB9AALDH1A1 | |
| SCHEMBL30884776 | 0.74 | ALDH1A1 (0.43) | BAZ2BRXFP1NPC1RAB9AALDH1A1 | |
| SCHEMBL19995829 | 0.74 | ALDH1A1 (0.47) | BAZ2BRXFP1NPC1RAB9AALDH1A1 | |
| SCHEMBL990238 | 0.72 | BAZ2B (0.46) | BAZ2BRXFP1NPC1RAB9AALDH1A1 | |
| SCHEMBL2318021 | 0.72 | BAZ2B (0.46) | BAZ2BRXFP1NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2831053-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2831053-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2831053-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2015-02-04 | — | — | EP | disclosed |
| WO-2013144098-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013144098-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
| EP-1680447-A2 | ORTHOGONAL GENE SWITCHES | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2006-07-19 | — | — | EP | disclosed |
| EP-1339683-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1339683-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005040212-A2 | ORTHOGONAL GENE SWITCHES | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2005-05-06 | — | — | WO | disclosed |
| EP-1339683-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002041835-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087346-A1 | Orthogonal gene switches | TCF12, JUN, TCF7 | BAZ2B 219/4885RXFP1 2543/4885NPC1 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.